Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone847-279-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$694.02 million
Profitability
Miscellaneous
Employees2,308
Next Earnings DateN/A
OptionableOptionable
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn, Inc. (NASDAQ:AKRX) released its earnings results on Thursday, February, 28th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.28. The firm had revenue of $153.39 million for the quarter, compared to the consensus estimate of $164.75 million. Akorn had a negative return on equity of 13.34% and a negative net margin of 57.91%. Akorn's revenue was down 17.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.14 EPS. View Akorn's Earnings History.
What price target have analysts set for AKRX?
6 equities research analysts have issued 1 year price targets for Akorn's stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Akorn's share price to reach $6.60 in the next twelve months. This suggests a possible upside of 92.4% from the stock's current price. View Analyst Price Targets for Akorn.
What is the consensus analysts' recommendation for Akorn?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn.
Has Akorn been receiving favorable news coverage?
Media stories about AKRX stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Arrowhead Pharmaceuticals (ARWR), Myovant Sciences (MYOV), Zai Lab (ZLAB), Allakos (ALLK), Pacira Pharmaceuticals (PCRX), Opko Health (OPK), Puma Biotechnology (PBYI), Prestige Consumer Healthcare (PBH), Wave Life Sciences (WVE), Innoviva (INVA), Gossamer Bio (GOSS), Aimmune Therapeutics (AIMT), Clovis Oncology (CLVS), Theravance Biopharma (TBPH) and Cambrex (CBM).
What other stocks do shareholders of Akorn own?
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Jonathan Kafer, Chief Commercial Officer (Age 56)
- Dr. Bruce Kutinsky, Consultant (Age 53)
- Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)
Who are Akorn's major shareholders?
Akorn's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.52%), Dimensional Fund Advisors LP (2.11%), Dimensional Fund Advisors LP (2.11%), Millennium Management LLC (1.65%), Two Sigma Investments LP (1.40%) and Bank of New York Mellon Corp (1.22%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky, John N Kapoor and Joseph Bonaccorsi. View Institutional Ownership Trends for Akorn.
Which major investors are selling Akorn stock?
AKRX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, American International Group Inc., Northern Trust Corp, FMR LLC, Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC., MetLife Investment Advisors LLC and Bank of America Corp DE. View Insider Buying and Selling for Akorn.
Which major investors are buying Akorn stock?
AKRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Norges Bank, Millennium Management LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Assenagon Asset Management S.A., Two Sigma Investments LP and Diag Capital Management LP. View Insider Buying and Selling for Akorn.
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $3.43.
How big of a company is Akorn?
Akorn has a market capitalization of $430.74 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,308 workers across the globe.
What is Akorn's official website?
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (NASDAQ AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
